The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I trial of adjuvant autogene cevumeran, an individualized mRNA neoantigen vaccine, for pancreatic ductal adenocarcinoma.
 
Vinod P. Balachandran
Research Funding - Genentech/Roche (Inst)
Patents, Royalties, Other Intellectual Property - Inventors on a patent application related to work on antigen cross-reactivity and on a patent application related to work on neoantigen quality modeling.
 
Luis A. Rojas
Employment - LEXEO Therapeutics (I); Rocket Pharma (I)
Stock and Other Ownership Interests - LEXEO Therapeutics (I); Rocket Pharma (I)
Patents, Royalties, Other Intellectual Property - Inventor on a patent application related to antigen cross-reactivity.; Inventor on a patent related to manufacturing of recombinant viral vectors. (I); Inventor on a patent related to oncolytic viral therapy
 
Zachary Sethna
Patents, Royalties, Other Intellectual Property - Co-inventor on a provisional patent application for a model of the T cell crossreactivity of peptides; Named as a contributing inventor on a patent application for a model of tumor fitness of p53 mutations
 
Kevin Soares
No Relationships to Disclose
 
Evelyna Derhovanessian
Employment - BioNTech SE
Stock and Other Ownership Interests - BioNTech SE
Patents, Royalties, Other Intellectual Property - BioNTech SE
 
Felicitas Mueller
Employment - BioNTech SE
Leadership - BioNTech SE
Stock and Other Ownership Interests - BioNTech SE
Other Relationship - TRON Translational Oncology Mainz
 
Mahesh Yadav
Employment - Abbvie/Stemcentrx (I); Roche/Genentech
Stock and Other Ownership Interests - Abbvie (I); Advaxis (I); BioLineRx (I); BioNTech (I); Celldex; ChemoCentryx (I); Evofem (I); Inovio Pharmaceuticals (I); Kintara Therapeutics (I); Nektar (I); Roche/Genentech; Seres Therapeutics (I)
 
Olca Basturk
No Relationships to Disclose
 
Mithat Gonen
Travel, Accommodations, Expenses - Genentech
 
Alice Chia-chi Wei
Honoraria - AstraZeneca Canada; Medtronic
Consulting or Advisory Role - Biosapien; Histosonics
 
Michael Ian D'Angelica
No Relationships to Disclose
 
T. Peter Kingham
No Relationships to Disclose
 
Benjamin Greenbaum
Stock and Other Ownership Interests - ROME Therapeutics; Shennon Biotechnologies
Honoraria - Merck
Consulting or Advisory Role - DarwinHealth; ROME Therapeutics
Research Funding - Bristol-Myers Squibb; Merck
Patents, Royalties, Other Intellectual Property - ROME Therapeutics
Travel, Accommodations, Expenses - Rome Therapeutics
 
Taha Merghoub
Stock and Other Ownership Interests - Imvaq therapeutics
Honoraria - Leap Therapeutics; Pfizer
Consulting or Advisory Role - ImmunoGenesis; Immunos Therapeutics
Research Funding - BMS; Surface Oncology
Patents, Royalties, Other Intellectual Property - inventor on patent applications related to work on oncolytic viral therapy, alphavirus-based vaccines, neo-antigen modeling, CD40, GITR, OX40, PD-1 and CTLA-4.
 
William R. Jarnagin
No Relationships to Disclose
 
Jeffrey A. Drebin
Employment - American Regent (I)
Leadership - American Regent (I)
Stock and Other Ownership Interests - Alnylam; Arrowhead Pharmaceuticals; Ions Pharmaceuticals
 
Ugur Sahin
Employment - BioNTech SE
Leadership - BioNTech SE
Stock and Other Ownership Interests - BioNTech SE
Research Funding - BioNTech SE
Patents, Royalties, Other Intellectual Property - BioNTech SE; Tron
Other Relationship - TRON Translational Oncology Mainz
 
Oezlem Tuereci
Employment - BioNTech SE
Leadership - BioNTech SE
Stock and Other Ownership Interests - BioNTech SE
Research Funding - BioNTech SE
Patents, Royalties, Other Intellectual Property - BioNTech SE; Tron
Other Relationship - Tron
 
Jedd D. Wolchok
Stock and Other Ownership Interests - Apricity Therapeutics; Arsenal IO; Ascentage Pharma; Beigene; Georgiamune; Imvaq Therapeutics; Linnaeus Therapeutics; Maverick Therapeutics; Tizona Therapeutics, Inc.; Trieza Therapeutics
Consulting or Advisory Role - Amgen; Apricity Therapeutics; Ascentage Pharma; AstraZeneca; Bicara Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; CellCarta; Daiichi Sankyo,Inc; Dragonfly Therapeutics; Georgiamune; Idera; Imvaq Therapeutics; Larkspur; Maverick Therapeutics; PsiOxus Therapeutics; Recepta Biopharma; Sellas Life Sciences; Surface Oncology; Tizona Therapeutics, Inc.; Trishula Therapeutics; Truvax; Werewolf Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Sephora
Patents, Royalties, Other Intellectual Property - ALPHAVIRUS REPLICON PARTICLES EXPRESSING TRP2 (Inst); Anti-GITR antibodies and methods of use thereof (Inst); Antigen-binding proteins targeting melanoma differentiation antigens and uses thereof (Inst); Antigen-binding proteins targeting melanoma differentiation antigens and uses thereof CTLA 4 (Inst); CD40 BINDING MOLECULES AND USES THEREOF (Inst); CD40 binding Molecules and uses thereof (Inst); Engineered Vaccinia Viruses for Cancer Immunotherapy (Inst); I am a co-inventor and receive royalties for a blood test for monitoring myeloid derived suppressor cells. (Inst); I am a co-inventor on a patent for Anti-CD40 agonist mAb fused to Monophosphoryl Lipid A (MPL) for cancer therapy (Inst); I am a co-inventor on a patent for CAR+ T cells targeting differentiation antigens as means to treat cancer (Inst); I am a co-inventor on a patent for use of oncolytic Newcastle Disease virus. (Inst); I am a co-inventor on an issued patent for DNA vaccines for treatment of cancer in companion animals. (Inst); I am co-inventor and receive royalties for a patent for immune modulating antibodies. (Inst); Immunosuppressive follicular helper-like T cells modulated by immune checkpoint blockade (Inst); Peripheral Blood Phenotype Linked to Outcomes After Immunotherapy Treatment (Inst); Phosphatidylserine Targeting Agents and uses thereof for adoptive T-cell therapies (Inst); RECOMBINANT POXVIRUSES FOR CANCER IMMUNOTHERAPY (Inst); WITH IMMUNOMODULATORY THERAPEUTICS AND METHOD OF MONITORING ABSCOPAL EFFECTS DURING SUCH TREATMENT (Inst)
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Adicet Bio (I); Alnylam (I); AstraZeneca (I); Autem Medical (I); BeiGene (I); Berry Genomics (I); BioSapien; BioSapien; Boehringer Ingelheim; Cend Therapeutics; CytomX Therapeutics; CytomX Therapeutics; Eisai (I); Exelixis (I); Flatiron Health (I); Genentech/Roche (I); Genoscience Pharma (I); Helio Health (I); IDEAYA Biosciences; Incyte (I); Ipsen (I); Legend Biotech (I); Merck; Nerviano Medical Sciences (I); Novartis; Noxxon Pharma; QED Therapeutics (I); Rafael Pharmaceuticals; RedHill Biopharma (I); Seagen; Thetis Pharma; Yiviva (I)
Research Funding - Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Celgene (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Parker Institute for Cancer Immunotherapy (Inst); Roche (Inst); Silenseed (Inst)